Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 2 of 58, showing 10 Applications out of 576 total, starting on record 11, ending on 20

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

11.

ECCT/19/07/01   IMPROVE-2
      chemoprevention with monthly IPTp with dihydroartemisinin-piperaquine for malaria in HIV-infected pregnant participants on daily cotrimoxazole in Kenya and Malawi: a multi-centre placebo-controlled trial(IMPROVE-2).    
Principal Investigator(s)
1. Hellen Cherono Barsosio
2. Simon Kariuki
Site(s) in Kenya
1. Ahero Sub-County Hospital (Kisumu county)
2. Rabuor Sub-County Hospital (Kisumu county)
3. Akala Sub-County Hospital (Siaya county)
 
03-10-2019 View

12.

ECCT/19/06/03   Evaluation of the RTS,S vaccine implementation in Kenya (MVPE)
      An evaluation of the cluster-randomised pilot implementation of the RTS,S/AS01 malaria vaccine through routine health systems in western Kenya         
Principal Investigator(s)
1. Aaron Samuels Samuels
Site(s) in Kenya
1. Bungoma County (Bung\'oma county)
2. Busia County (Busia county)
3. Homa Bay (Homa Bay county)
4. Kakamega County (Kakamega county)
5. Kisumu County (Kisumu county)
6. Migori County (Migori county)
7. Siaya County (Siaya county)
8. Vihiga County (Vihiga county)
 
13-08-2019 View

13.

ECCT/26/02/01   E-MASTER STUDY: PHASE 1
      Diagnosis of postpartum haemorrhage at caesarean section: a multi-country diagnostic and prognostic accuracy study (E-MASTER: PHASE 1)        
Principal Investigator(s)
1. Zahida Qureshi
2. Alfred Osoti
3. George Gwako
Site(s) in Kenya
1. Mbagathi County Referral Hospital (Nairobi City county)
 
19-06-2026 View

14.

ECCT/22/01/01   ASTEFANIA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
21-07-2022 View

15.

ECCT/24/04/05   Phase III Vitiligo Study
                                                                             A Double-Arm, Open Label, Phase III Study to Compare the                                           Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-                                                                                    UVB Light Alone in the Treatment of Vitiligo   
Principal Investigator(s)
1. Dr. Hannah Wanyika Wanyika
Site(s) in Kenya
Kenyatta National Hospital -
 
30-08-2024 View

16.

ECCT/23/02/03   INTREPiD
    Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy with High-Sensitivity Diagnostics (INTREPiD).   
Principal Investigator(s)
1. Steve M Taylor
2. Jeremiah K Laktabai
Site(s) in Kenya
Bungoma County
 
23-07-2023 View

17.

ECCT/22/09/03   SINGLE DOSE VERSUS EXTENDED DO
    EFFECTIVENESS OFSINGLE-DOSE ANTIBIOTIC USE IN ELECTIVE CAESAREANSECTION IN PREVENTION OF SURGICAL SITE INFECTION AT JARAMOGI    OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL, KISUMU COUNTY,KENYA: A RANDOMIZED CONTROL TRIAL.   
Principal Investigator(s)
1. STEVEN ODHIAMBO JUMA
Site(s) in Kenya
JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL
 
26-09-2022 View

18.

ECCT/16/10/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Professor Walter Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Research (Nairobi City county)
2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
 
13-02-2017 View

19.

ECCT/21/07/02   TALIOS
    A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
01-11-2021 View

20.

ECCT/11/04/01  
    A Double-blind, Randomized Trial of Monthly Treatment with Metronidazole and Miconazole Co-formulated Suppositories versus Placebo for Preventing Vaginal Infections in HIVSeronegative Women (DMID Protocol Number: 09-0070)   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Kenya AIDS Vaccine Initiative (Nairobi City county)
2. Kenya AIDS Control Program (Nairobi City county)
3. Mombasa HIV/STD Research Clinic (Mombasa county)
 
23-06-2011 View